Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE

European Journal of Heart Failure

Volumn 8, Issue 5, 2006, Pages 451-459

  Kovacs, Imre ^a   Toth, Janos ^b   Tarjan, Jeno ^a   Koller, Akos ^b,c  

^a Markusovszky Teaching Hospital   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Endothelial function; Flow mediated dilatation; Tissue renin angiotensin system; Vascular inflammation

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; QUINAPRIL; TUMOR NECROSIS FACTOR ALPHA;

ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; FEMALE; HEART DISEASE; HEART FUNCTION; HEART INFARCTION; HUMAN; HYPOTHESIS; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; ENALAPRIL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; STROKE VOLUME; TETRAHYDROISOQUINOLINES; TUMOR NECROSIS FACTOR-ALPHA; ULTRASONOGRAPHY, DOPPLER; VASODILATION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 33747250064     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2005.10.011     Document Type: Article

References (65)

1. Drexler H., Hayoz D., Munzel T., et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 69 (1992) 1596-1601
2. Drexler H., Hayoz D., Munzel T., Just H., Zelis R., and Brunner H.R. Endothelial function in congestive heart failure. Am Heart J 126 (1993) 761-764
3. Sun D., Huang A., Zhao G., et al. Reduced NO-dependent arteriolar dilation during the development of cardiomyopathy. Am J Physiol Heart Circ Physiol 278 (2000) H461-H468
4. Stathopulos P.B., Lu X., Shen J., et al. Increased l-arginine uptake and inducible nitric oxide synthase activity in aortas of rats with heart failure. Am J Physiol Heart Circ Physiol 280 (2001) H859-H867
5. Hayoz D., Drexler H.M.T., Hornig B., et al. Flow-mediated arteriolar dilation is abnormal in congestive heart failure. Circulation 87 Suppl VII (1993) VII-92-VII-96
6. Koller A., Huang A., Sun D., and Kaley G. Exercise training augments flow-dependent dilation in rat skeletal muscle arterioles. Role of endothelial nitric oxide and prostaglandins. Circ Res 76 (1995) 544-550
7. Koller A., and Huang A. Development of nitric oxide and prostaglandin mediation of shear stress-induced arteriolar dilation with aging and hypertension. Hypertension 34 (1999) 1073-1079
8. Nakamura M., Funakoshi T., Arakawa N., Yoshida H., Makita S., and Hiramori K. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol 24 (1994) 1321-1327
9. Hornig B., Arakawa N., Haussmann D., and Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 98 (1998) 2842-2848
10. Hornig B., Arakawa N., and Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 19 Suppl G (1998) G48-G53
11. Swedberg K., Kjekshus J., and Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 20 (1999) 136-139
12. Dzau V.J., Bernstein K., and Celermajer D. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 88 (2001) 1L-20L
13. Mombouli J.V., Illiano S., Nagao T., Scott-Burden T., and Vanhoutte P.M. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ Res 71 (1992) 137-144
14. Koller A., Rodenburg J.M., and Kaley G. Effects of Hoe-140 and ramiprilat on arteriolar tone and dilation to bradykinin in skeletal muscle of rats. Am J Physiol 268 (1995) H1628-H1633
15. Ferrari R., Agnoletti L., Comini L., et al. Oxidative stress during myocardial ischaemia and heart failure. Eur Heart J 19 Suppl B (1998) B2-B11
16. Hornig B., Arakawa N., Kohler C., and Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 97 (1998) 363-368
17. Hornig B., Landmesser U., Kohler C., et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 103 (2001) 799-805
18. Zhou M.S., Jaimes E.A., and Raij L. Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am J Hypertens 17 (2004) 167-171
19. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20 (1992) 248-254
20. Blum A., and Miller H. Role of cytokines in heart failure. Am Heart J 135 (1998) 181-186
21. Aukrust P., Ueland T., Lien E., et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83 (1999) 376-382
22. Habib F.M., Springall D.R., Davies G.J., Oakley C.M., Yacoub M.H., and Polak J.M. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 347 (1996) 1151-1155
23. Mold C., Gewurz H., and Clos T.W. Regulation of complement activation by C-reactive protein. Immunopharmacology 42 (1999) 23-30
24. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
25. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
26. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., and Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106 (2002) 1439-1441
27. Huang A., Sun D., Kaley G., and Koller A. Superoxide released to high intra-arteriolar pressure reduces nitric oxide-mediated shear stress- and agonist-induced dilations. Circ Res 83 (1998) 960-965
28. Ungvari Z., Csiszar A., Huang A., Kaminski P.M., Wolin M.S., and Koller A. High pressure induces superoxide production in isolated arteries via protein kinase C-dependent activation of NAD(P)H oxidase. Circulation 108 (2003) 1253-1258
29. Ungvari Z., Csiszar A., Kaminski P.M., Wolin M.S., and Koller A. Chronic high pressure-induced arterial oxidative stress: involvement of protein kinase C-dependent NAD(P)H oxidase and local renin-angiotensin system. Am J Pathol 165 (2004) 219-226
30. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111-1115
31. Kovacs I., Toth J., and Koller A. Quinapril improves flow mediated dilatation (FMD) in patients with impaired cardiac function; correlation between FMD, CRP and TNF-alpha. Eur J Heart Fail Suppl 3 (2004) [28/108 (abstract)]
32. Tarjan J. Effect of AT1-receptor antagonists on endothelial function. In: Rubanyi G.M., Dzau V.J., and Cooke J.P. (Eds). Vascular protection (2002), Taylor and Francis, London and New York 85-95
33. Hornig B., Maier V., and Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 93 (1996) 210-214
34. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
35. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
36. Varela-Roman A., Gonzalez-Juanatey J.R., Basante P., et al. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart 88 (2002) 249-254
37. Yan R., Anderson T.J., Charbonneau F., Title L., Verma S., and Lonn E. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. Am Coll Cardiol 45 (2005) 1980-1986
38. Rossi R., Chiurlia E., Nuzzo A., Cioni E., Origliani G., and Modena M.G. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women. J Am Coll Cardiol 44 (2004) 1636-1640
39. Ol'binskaia L.I., Ignatenko S.B., and Markin S.S. Tumor necrosis factor in blood plasma and morphofunctional parameters of the hart in patients with chronic heart failure complicated by a course of ischemic heart disease. Dynamics under effect of treatment. Ter Arkh 75 (2003) 54-58
40. Yin W.H., Chen J.W., Jen H.L., et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 147 (2004) 931-938
41. Koller A., and Kaley G. Endothelial regulation of wall shear stress and blood flow in skeletal muscle microcirculation. Am J Physiol 260 (1991) H862-H868
42. Benzing T., Fleming I., Blaukat A., Muller-Esterl W., and Busse R. Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 99 (1999) 2034-2040
43. Kohlstedt K., Brandes R.P., Muller-Esterl W., Busse R., and Fleming I. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res 94 (2004) 60-67
44. Koh K.K.B.M., Hathaway L., Csako G., Waclawiw M.A., Panza J.A., and Cannon III R.O. Mechanism by which quinapril improves vascular function in coronary artery disease. Am J Cardiol 83 (1999) 327-331
45. Levy B.I., Salzmann J.L., Devissaguet M., Safar M.E., and Michel J.B. Angiotensin converting enzyme (ACE) inhibitors in experimental hypertension: influence on heart and arteries. Basic Res Cardiol 86 Suppl 1 (1991) 43-53
46. Csiszar A., Ungvari Z., Koller A., Edwards J.G., and Kaley G. Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. Physiol Genomics 17 (2004) 21-30
47. Ungvari Z., Csiszar A., Edwards J.G., et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 23 (2003) 418-424
48. Touyz R.M., Chen X., Tabet F., et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 90 (2002) 1205-1213
49. Holycross B.J., and Radin M.J. Cytokines in heart failure: potential interactions with angiotensin II and leptin. Mol Interv 2 (2002) 424-427
50. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
51. Sun Y., Zhang J., Lu L., Bedigian M.P., Robinson A.D., and Weber K.T. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 143 (2004) 41-51
52. Hashimoto H., Kitagawa K., Hougaku H., et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 104 (2001) 63-67
53. Taylor S.H. A comparison of the efficacy and safety of quinapril with that of enalapril in the treatment of mild to moderate essential hypertension. Angiology 40 (1989) 382-388
54. Sanchez S., Luna A., Orozco R., and Velasco G. Quinapril versus enalapril in the treatment of mild-to-moderate essential hypertension. Clin Ther 13 (1991) 651-655
55. Posvar E.L., and Sedman A.J. ACE inhibitors in the elderly. Angiology 42 (1991) 387-396
56. Lyons D., Webster J., and Benjamin N. Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol 51 (1997) 373-378
57. Junot C., Nicolet L., Ezan E., Gonzales M.F., Menard J., and Azizi M. Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats. J Pharmacol Exp Ther 291 (1999) 982-987
58. Michel B., Grima M., Stephan D., et al. Plasma renin activity and changes in tissue angiotensin converting enzyme. J Hypertens 2 (1994) 577-584
59. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 327 (1992) 685-691
60. Hall A.S., Winter C., Bogle S.M., Mackintosh A.F., Murray G.D., and Ball S.G. The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions. J Cardiovasc Pharmacol 18 Suppl 2 (1991) S105-S109
61. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342 (1993) 821-828
62. Coca A., and Rabasseda X. Trandolapril in left ventricular dysfunction after myocardial infarction: focus on the TRACE study. Drugs Today (Barc) 39 (2003) 5-18
63. Kober L., Torp-Pedersen C., Jorgensen S., Eliasen P., and Camm A.J. Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Am J Cardiol 81 (1998) 1292-1297
64. Meyer T.E., Karamanoglu M., Ehsani A.A., and Kovacs S.J. Left ventricular chamber stiffness at rest as a determinant of exercise capacity in heart failure subjects with decreased ejection fraction. J Appl Physiol 97 (2004) 1667-1672
65. Hegele R.A. Angiotensin-converting enzyme (ACE) inhibition in the secondary prevention of vascular disease: the Heart Outcomes Prevention Evaluation (HOPE) Trial and its substudies. Curr Atheroscler Rep 2 (2000) 361-362